Floriana Morgillo

TL;DR: This review focalizes some of these intricate events by discussing the relationships occurring among oxidative/nitrosative/metabolic stress, inflammation and cancer.

TL;DR: Experimental and clinical evidence supporting the use of KRAS testing for the optimal selection of patients with mCRC to be treated with anti-EGFR monoclonal antibodies is summarized.

TL;DR: The published literature and abstracts of oral and poster presentations from international conferences addressing EGFR-TKIs resistance mechanisms discovered in preclinical models and in patients with NSCLC are reviewed.

TL;DR: In unselected patients with advanced NSCLC, first- line erlotinib followed at progression by cisplatin-gemcitabine was significantly inferior in terms of overall survival compared with the standard sequence of first-line chemotherapy followed by erlot inib.

TL;DR: All data on treatment options feasible for pulmonary LCNEC, both for localized and extensive disease are reviewed, with SCLC-like chemotherapy seems the best option of treatment, with a good response rate but a poor overall survival.